COVID-19 has presented one of the greatest challenges of the century, but with it comes an opportunity to change the way we approach Emerging Infectious Diseases (EIDs), and global health in general. BioTav leverages decades of experience developing and manufacturing veterinary and human vaccines, to create breakthrough solutions for the COVID-19 caused by SARS-CoV-2 and other viral pandemics.
As advocates of the One Health approach, that recognizes the interdependence of human, animal, and environmental health, BioTav’s cumulative experience enables more efficient production and utilization of immunoglobulins, shorter development times, and improved accessibility to critical immunizations.
Groundbreaking hyperimmune Yolk Immunoglobulins (IgY) in the form of nasal spray, for trating the diesease after expousure.
Innovative attenuated live vaccine to prevent infection, with optimal safety and efficacy.
Treatment of glioma tumors that leverages oncolytic activity of Newcastle Disease Virus (NDV)
Two provisional patents pending, validated methodology in a pilot lab, operating a GMP production facility, and preparing for large-scale production.
By taking two approaches to COVID-19 immunity – active and passive – BioTav is expediting protective immunity compared to other means of immunizing populations against mutating and adaptive strains of viruses.
Based on a modified, asymptomatic version of the virus, BioTav’s live attenuated vaccine is expected to show extremely high efficacy compared to forecasts for recombinant vaccines and nucleic acid vaccines currently in development. For passive immunity, BioTav has developed a hyperimmune Yolk Immunoglobulins (IgY), over-the-counter mucosal spray, based on a proven approach and validated methodology. Administered at the stage where early signs of infection are present, this revolutionary solution ensures greater accessibility to treatment and immunization. As both the nasal spray and the live attenuated vaccines are based on safe and proven biopharmaceutical approaches, solutions will be classified as a Class II devices, ensuring shorter development time and faster response to current pandemic and other EIDs.
BioTav has reached seed material phase and is ready for clinical trials to prove oncolytic activity of Newcastle Disease Virus (NDV) for the treatment of glioma tumors in humans.
Glioblastoma (GBM) is the most aggressive and common primary brain tumor in adults, with a median overall survival of 15 months. Tumor recurrence and poor prognosis are related to cancer stem cells (CSCs), which drive resistance to therapies. NDV has been evaluated for the treatment of glioma in early-phase in vivo studies, with the combined therapy yielding significantly smaller tumor volumes and significantly longer median survival times.